Fortune May 25, 2023
Giacomo Chiesi

Rare diseases have gained more attention in recent years, perhaps in part due to the high price tags often associated with approved therapies. But the cost of rare disease drugs is dwarfed by the cost of not having them.

Our recent study shows that a lack of treatment for a rare disease is associated with a 21.2% increase in total costs per patient per year. That places a significant burden on the healthcare system. While rare diseases impact a small population, the cost to society is staggering–we estimate that the societal cost in the U.S. for all 7,000 known rare diseases may be in the range of $7.2-$8.6 trillion per year.

Historically, there has been a lack of...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Pricing / Spending, Provider, Survey / Study, Trends
How To Analyze And Improve The Usability Of Insurer Price Transparency Data
How four major payers compare on price transparency
Commercial Insurer Price Transparency: A Comparison Of Four National Payers
Fat Joe enlists fellow rappers in hospital price transparency campaign
CMS proposes changes to increase Medicaid drug price transparency

Share This Article